Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors
Background. The purpose of the study was to evaluate Sorafenib (BAY 43-9006) derived receptor tyrosine kinase inhibition on tumor progression in murine islet cell tumors. Sorafenib is considered to be a potent inhibitor of tumor angiogenesis and neovascularization in various solid tumors. Rip1Tag2 m...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/529151 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849395259118714880 |
|---|---|
| author | Volker Fendrich Katja Maschuw Johannes Rehm Malte Buchholz Julia P. Holler Emily P. Slater Detlef K. Bartsch Jens Waldmann |
| author_facet | Volker Fendrich Katja Maschuw Johannes Rehm Malte Buchholz Julia P. Holler Emily P. Slater Detlef K. Bartsch Jens Waldmann |
| author_sort | Volker Fendrich |
| collection | DOAJ |
| description | Background. The purpose of the study was to evaluate Sorafenib (BAY 43-9006) derived receptor tyrosine kinase inhibition on tumor progression in murine islet cell tumors. Sorafenib is considered to be a potent inhibitor of tumor angiogenesis and neovascularization in various solid tumors. Rip1Tag2 mice were treated in two different groups according to the model of tumor progression: the early treatment group received vehicle or Sorafenib from 10 to 14 weeks of age and the late treatment group from week 12 until death. Tumor surface, tumor cell proliferation, and apoptosis were measured in both treatment groups to assess the in vivo effects of Sorafenib. Survival was recorded for the late treatment group. In the early treatment group Sorafenib led to a dramatic decrease in tumor volume compared to the control group. Apoptosis was significantly augmented and cell proliferation was inhibited. As a single therapy Sorafenib significantly improved survival in the late treatment group. Conclusion. Sorafenib may provide a new paradigm for the therapy of islet cell tumors. |
| format | Article |
| id | doaj-art-ad8a3fc3c38d489985992108a4888dd6 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-ad8a3fc3c38d489985992108a4888dd62025-08-20T03:39:41ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/529151529151Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell TumorsVolker Fendrich0Katja Maschuw1Johannes Rehm2Malte Buchholz3Julia P. Holler4Emily P. Slater5Detlef K. Bartsch6Jens Waldmann7Department of Surgery, University Hospital Giessen and Marburg, Baldinger Strasse, 35043 Marburg, GermanyDepartment of Surgery, University Hospital Giessen and Marburg, Baldinger Strasse, 35043 Marburg, GermanyDepartment of Surgery, University Hospital Giessen and Marburg, Baldinger Strasse, 35043 Marburg, GermanyDepartment of Gastroenterology and Endocrinology, University Hospital Giessen and Marburg, Marburg, GermanyDepartment of Surgery, University Hospital Giessen and Marburg, Giessen, GermanyDepartment of Surgery, University Hospital Giessen and Marburg, Baldinger Strasse, 35043 Marburg, GermanyDepartment of Surgery, University Hospital Giessen and Marburg, Baldinger Strasse, 35043 Marburg, GermanyDepartment of Surgery, University Hospital Giessen and Marburg, Baldinger Strasse, 35043 Marburg, GermanyBackground. The purpose of the study was to evaluate Sorafenib (BAY 43-9006) derived receptor tyrosine kinase inhibition on tumor progression in murine islet cell tumors. Sorafenib is considered to be a potent inhibitor of tumor angiogenesis and neovascularization in various solid tumors. Rip1Tag2 mice were treated in two different groups according to the model of tumor progression: the early treatment group received vehicle or Sorafenib from 10 to 14 weeks of age and the late treatment group from week 12 until death. Tumor surface, tumor cell proliferation, and apoptosis were measured in both treatment groups to assess the in vivo effects of Sorafenib. Survival was recorded for the late treatment group. In the early treatment group Sorafenib led to a dramatic decrease in tumor volume compared to the control group. Apoptosis was significantly augmented and cell proliferation was inhibited. As a single therapy Sorafenib significantly improved survival in the late treatment group. Conclusion. Sorafenib may provide a new paradigm for the therapy of islet cell tumors.http://dx.doi.org/10.1100/2012/529151 |
| spellingShingle | Volker Fendrich Katja Maschuw Johannes Rehm Malte Buchholz Julia P. Holler Emily P. Slater Detlef K. Bartsch Jens Waldmann Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors The Scientific World Journal |
| title | Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors |
| title_full | Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors |
| title_fullStr | Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors |
| title_full_unstemmed | Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors |
| title_short | Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors |
| title_sort | sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors |
| url | http://dx.doi.org/10.1100/2012/529151 |
| work_keys_str_mv | AT volkerfendrich sorafenibinhibitstumorgrowthandimprovessurvivalinatransgenicmousemodelofpancreaticisletcelltumors AT katjamaschuw sorafenibinhibitstumorgrowthandimprovessurvivalinatransgenicmousemodelofpancreaticisletcelltumors AT johannesrehm sorafenibinhibitstumorgrowthandimprovessurvivalinatransgenicmousemodelofpancreaticisletcelltumors AT maltebuchholz sorafenibinhibitstumorgrowthandimprovessurvivalinatransgenicmousemodelofpancreaticisletcelltumors AT juliapholler sorafenibinhibitstumorgrowthandimprovessurvivalinatransgenicmousemodelofpancreaticisletcelltumors AT emilypslater sorafenibinhibitstumorgrowthandimprovessurvivalinatransgenicmousemodelofpancreaticisletcelltumors AT detlefkbartsch sorafenibinhibitstumorgrowthandimprovessurvivalinatransgenicmousemodelofpancreaticisletcelltumors AT jenswaldmann sorafenibinhibitstumorgrowthandimprovessurvivalinatransgenicmousemodelofpancreaticisletcelltumors |